Our Work in Nephrology
Renal patients are among the most challenging to manage due to multiple co-morbidities and poor outcomes. Nephrologists see a wide array of patients including those across all five stages of chronic kidney disease, those on dialysis and those with kidney transplants. At Spherix, we have an intimate understanding of the US dialysis market, unparalleled perspective on hospital-based nephrology practice and a unique glimpse into the patient flow within private practice nephrology.
Renal Anemia, Chronic Kidney Disease, Dialysis, Diabetic Nephropathy, Hyperkalemia, Hyperphosphatemia, Renal Anemia, SHPT and Lupus Nephritis.
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with disease in nephrology and those who are close to them.
The Renal Anemia Market is on the Cusp of Change Beginning with the FDA Approval of Keryx Biopharmaceutical’s Auryxia for the Treatment of Iron Deficiency Anemia (IDA) in Adults with Chronic Kidney Disease, Not on Dialysis (CKD-ND) – November 7, 2017
Changes Afoot in the Management of CKD Mineral Bone Disorder Reinforced by a Clinical Practice Guideline Update from KDIGO – August 10, 2017
New Study of More Than 1,000 Dialysis Patients Reveals Significant Opportunity for Improvement of Hyperphosphatemia and Highlights the Potential for Amgen’s Parsabivt – August 3, 2017
American Society of Nephrology 2017 Conference